Frontier Pharma and Baystone Group completes its acquisition of Zdravlje, a high quality pharmaceutical manufacturer in Serbia
PR88746
LONDON and BELGRADE, Serbia, April 1, 2021 /PRNewswire=KYODO JBN/ --
- Zdravlje is a leading pharmaceutical manufacturer which supplies more than
35 countries around the world
- The Company has a 65+ year track record in supplying high quality
pharmaceutical products across oral solid and liquid forms
- Zdravlje represents a solid foundation upon which a leading international
pharmaceutical platform will be built over the coming years
Frontier Pharma [ http://www.frontierpharma.co.uk/ ]and Baystone Group today
announced the completion of its acquisition of Zdravlje A.D
[http://www.zdravlje.co.rs/ ]from Teva Pharmaceuticals. Zdravlje currently
supplies high quality pharmaceuticals to more than 35 international markets
including those in Western & Eastern Europe, U.K., Asia-Pacific, Sub-Saharan
Africa and Latin America.
"We are incredibly pleased to complete this transaction and support Zdravlje as
a leading independent pharmaceutical company. We look forward to working
together with the exceptionally talented team at Zdravlje to further develop
the Company into a leading international pharmaceutical company." said M.
Levent Selamoglu, Chairman of Frontier Pharma.
Established in 1953, Zdravlje has a 67 year track record in the manufacture and
supply of high quality pharmaceutical products. The Company currently employs
more than 250 people and manufactures a large portfolio of oral solid and
liquid products to treat a range of serious and chronic diseases including
cardiovascular, central nervous system and respiratory disorders, amongst
others. Zdravlje also brings a portfolio of complementary branded generic
pharmaceutical products which forms the foundation of an independent commercial
strategy under the "Zdravlje" brand.
"We look forward to leveraging Zdravlje's extensive track record as a premium
global supplier to create an industry-leading, fully integrated pharma
platform." said Kiren Naidoo, CEO of Frontier Pharma.
"This is a key milestone in Zdravlje's history and we are delighted to continue
our successful business in the pharmaceutical industry by providing our high
quality products to more than 35 countries around the world and to support the
local community in which we have successfully operated in for more than 67
years" said Bojan Jovic, Zdravlje's General Manager.
About Frontier Pharma and Baystone Group
Frontier Pharma is a U.K.-based specialist pharmaceutical investor and operator
founded by M. Levent Selamoglu and Kiren Naidoo. The company has several
decades of industry experience across Europe, Middle East and Africa ("EMEA").
The group is well-known for its capabilities across oral solids, injectables
and topical pharmaceutical forms, API production and experience as a contract
manufacturer for a range of multinationals.
The Baystone Group comprises U.K. and U.S.-based specialist pharma investors
closely associated with the growth of SICOR, Inc. and of the IVAX Corp, two
industry-leading specialty pharmaceutical companies with advanced capabilities
across injectables and respiratory technologies, amongst others. The Group is a
major shareholder in Flynn Pharma (comprising operations across the U.K.,
Ireland and Germany) and has a portfolio of pharmaceutical investments spanning
biotechnology and advanced drug delivery.
Source: Frontier Pharma
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。